BOSTON (TheStreet) -- News of a drug's approval or rejection from the U.S. Food and Drug Administration can rock or kill a biotech stock's price. Here are ten companies with drugs facing FDA approval decisions in the first half of this year.
Drug/indication: Horizant for restless leg syndrome
Approval decision date: Unknown
Xenoport said that the FDA extended the Horizant approval decision date to Feb. 11 from Feb. 9 due to severe winter weather that shut down Washington. Yet the Feb. 11 deadline came and went without any word on the drug's approval.
is Xenoport's marketing partner for Horizant.
: The FDA rejected Horizant Wednesday night, citing concerns about a potential link between the drug and pancreatic tumors in rats.
Drug/indication: Afrezza for diabetes
Approval decision date: Unknown
The Jan. 16 FDA approval decision date for Afrezza was extended because inspections at an insulin manufacturing facility were not yet completed, according to Mannkind. How long the FDA will take to complete its inspection and issue an approval decision for Afrezza, an inhaled insulin device, is not known. Last month, Mannkind executives expressed confidence that the FDA would be able to complete its review within weeks, but that timeline is already past due.
Drug/indication: Xifaxan for hepatic encephalopathy
Approval decision date: March 24
Salix will bring Xifaxan in front of an FDA advisory panel on Feb. 23, which will recommend to the FDA whether the drug should be approved or not. As part of these proceedings, the FDA will post its review of Xifaxan on its web site on Feb. 19 or 22.
Drug/indication: Velaglucerase for Gaucher's disease
Approval decision date: Feb. 28
If approved, "Vela" will trigger a marketing battle in Gaucher's disease against well-entrenched competitor and market leader Cerezyme, owned by
( AMLN) and
Drug/indication: Exenatide once weekly for diabetes
Approval decision date: March 5
Exenatide once weekly is a long-acting version of Exenatide, a once-daily injectable diabetes drug marketed by Amylin and
. Exenatide once weekly was developed with Alkermes' long-acting drug delivery technology; the company will receive royalties on the drug's sales.
Drug/indication: Pirfenidone for idiopathic pulmonary fibrosis
Approval decision date: May 4
Prior to the FDA's approval decision date, an FDA advisory panel will review the safety and efficacy of pirfenidone on March 9. The FDA's review of pirfenidone is expected to post to the agency's web site on March 5 or March 8.
Drug/indication: Silenor for insomnia
Approval decision date: March 21
The FDA issued a complete response letter for Silenor last December. Somaxon met with the FDA, submitted additional information about the drug's effect in non-elderly patients and now says the agency has all the data it needs to review the drug and issue an approval decision.
Drug/indication: Pixantrone for non-Hodgkin's lymphoma
Approval decision date: April 23
The FDA has not yet rescheduled an advisory panel meeting for pixantrone, which was postponed on Feb. 10 due to severe winter weather. Cell Therapeutics executives said that they expect a new advisory panel to convene in late February or early March.
Drug/indication: Provenge for prostate cancer
Approval decision date: May 1
The FDA has given no indication that it plans to hold an advisory panel meeting to review the Provenge application. A similar panel meeting was held in 2007, which voted to recommend the drug's approval.
Drug/indication: Vimovo for pain relief
Approval decision date: April 30
Vimovo combines an acid inhibitor with a non-steroidal anti-inflammatory drug in a single tablet, intended to provide pain relief with fewer gastrointestinal side effects.
is Pozen's marketing partner for Vimovo.
-- Reported by Adam Feuerstein in Boston.
>>Alkermes Testing Schizophrenia Drug
Follow Adam Feuerstein on
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.